Efficient isolation of novel human monoclonal antibodies with neutralizing activity against HIV-1 from transgenic mice expressing human Ig loci

Journal of Immunology

Volumn 169, Issue 1, 2002, Pages 595-605

  He, Yuxian ^a   Honnen, William J ^a   Krachmarov, Chavdar P ^a   Burkhart, Michael ^a   Kayman, Samuel C ^a   Corvalan, Jose ^a   Pinter, Abraham ^a  

^a PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EPITOPE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CELL TRANSFORMATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOTHERAPY; MOUSE; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; SPLEEN CELL; TRANSGENIC MOUSE; VACCINATION; VIRUS NEUTRALIZATION;

EID: 0036644329     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.169.1.595     Document Type: Article

References (73)

1. Prevalence, clinical significance, and strain specificity of neutralizing antibody to the human immunodeficiency virus
2. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection
3. Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F and I: Lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement
4. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals
5. Clinical, immunologic, and virologic observations related to human immunodeficiency virus (HIV) type 1 infection in a volunteer in an HIV-1 vaccine clinical trial
6. Human immunodeficiency virus type 1 infection despite prior immunization with a recombinant envelope vaccine regimen
7. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1
8. Genetic and immunologic characterization of viruses infecting MN-rgp 120-vaccinated volunteers
9. Immunological and virological analyses of persons infected by human immunodeficiency virus type 1 while participating in trials of recombinant gp120 subunit vaccines
10. Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines: AIDS Vaccine Evaluation Group and the Correlates of HIV Immune Protection Group
11. Viral envelope fails to deliver?
12. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody
13. Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120
14. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG
15. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1
16. Neutralization of primary human immunodeficiency virus type 1 isolates by the broadly reactive anti-V3 monoclonal antibody, 447-52D
17. Human monoclonal antibodies to the V3 loop of HIV-1 with intra- and interclade cross-reactivity
18. Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4 binding site of gp120
19. Rat monoclonal antibodies to nonoverlapping epitopes of human immunodeficiency virus type 1 gp120 block CD4 binding in vitro
20. An IgG human monoclonal antibody that reacts with HIV-1/gp120, inhibits virus binding to cells, and neutralizes infection
21. Synergistic inhibition of HIV-1 by CD4 binding domain reagents and V3 directed monoclonal antibodies
22. A human monoclonal antibody against the CD4 binding site of HIV-1 gp120 exhibits potent, broadly neutralizing activity
23. Human anti-V2 monoclonal antibody that neutralizes primary but not laboratory isolates of HIV-1
24. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS
25. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1
26. Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding
27. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals
28. Neutralizing recombinant human antibodies to a conformational V2- and CD4-binding site-sensitive epitope of HIV-1 gp120 isolated by using an epitope-masking procedure
29. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1
30. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1
31. Production of fully human antibodies by transgenic mice
32. Regulation of B cell development by variable gene complexity in mice reconstituted with human immunoglobulin yeast artificial chromosomes
33. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice
34. Transgenic mice as a source of fully human antibodies for the treatment of cancer
35. Fully human anti-interleukin-8 monoclonal antibodies: Potential therapeutics for the treatment of inflammatory disease states
36. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy
37. Isolates of human immunodeficiency virus type 1 from the brain may constitute a special group of the AIDS virus
38. Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms
39. Characterization of a human cell line transformed by DNA from human adenovirus type 5
40. The scanning model for translation: An update
41. Envelope glycoproteins of HIV-1, HIV-2, and SIV purified with Galanthus nivalis agglutinin induce strong immune responses
42. V3-specific polyclonal antibodies affinity-purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type-1
43. A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates
44. Distinct modes of human immunodeficiency virus type 1 proviral latency revealed by superinfection of nonproductively infected cell lines with recombinant luciferase-encoding viruses
45. Presentation of native epitopes in the V1/V2 and V3 domains of HIV-1 gp120 by fusion glycoproteins containing fragments of gp120
46. Sequence diversity of V1 and V2 domains of gp120 from human immunodeficiency virus type 1: Lack of correlation with viral phenotype
47. Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120
48. A novel glycan-dependent epitope in the V2 domain of human immunodeficiency virus type 1 gp120 is recognized by a highly potent neutralizing chimpanzee monoclonal antibody
49. Synergistic neutralization of HIV-1 by a chimpanzee monoclonal antibody against the V2 domain of gp120 in combination with monoclonal antibodies against the V3 loop and the CD4-binding site
50. Probing the structure of the V2 domain of human inmmnodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: Human immune response to the V1 and V2 domains
51. Discontinuous, conserved neutralization epitopes overlapping the CD4 binding region of the HIV-1 gp120 envelope glycoprotein
52. N-Linked glycosylation sites adjacent to and within the V1/V2 and the V3 loops of dualtropic human immunodeficiency virus type 1 isolate DH12 gp120 affect coreceptor usage and cellular tropism
53. Determinants of syncytium formation in microglia by human immunodeficiency virus type 1: Role of the V1/V2 domains
54. Alterations in the V1/V2 domain of HIV-2CBL24 glycoprotein 105 correlate with an extended cell tropism
55. The V1/V2 region of human immunodeficiency virus type 1 modulates the sensitivity to neutralization by soluble CD4 and cellular tropism
56. Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers
57. + T-cell-depleted rhesus macaques
58. Identification and characterization of monoclonal antibodies specific for polymorphic antigenic determinants within the V2 region of the human immunodeficiency virus type 1 envelope glycoprotein
59. Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody
60. Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120
61. Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the HIV-1 envelope glycoprotein
62. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120
63. Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody
64. Amino acid residues of the human immunodeficiency virus type 1 gp120 critical for the binding of rat and human monoclonal antibodies that block the gp120-sCD4 interaction
65. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
66. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding
67. The antigenic structure of the HIV gp120 envelope glycoprotein
68. A recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure
69. Characterization of stable, soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins
70. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease
71. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells